Neonc Technologies (NASDAQ:NTHI) Stock: Insider Amir Heshmatpour Purchases 30,000 Shares

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) CEO Amir Heshmatpour acquired 30,000 shares of the stock in a transaction dated Friday, November 13th. The stock was bought at an average cost of $5.02 per share, with a total value of $150,600.00. Following the completion of the purchase, the chief executive officer owned 3,353,000 shares of the company’s stock, valued at approximately $16,832,060. The trade was a 0.90% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Neonc Technologies Stock Up 1.2%

Shares of NTHI stock traded up $0.06 during trading hours on Friday, reaching $4.91. The company had a trading volume of 251,853 shares, compared to its average volume of 118,828. Neonc Technologies Holdings, Inc. has a 12 month low of $2.50 and a 12 month high of $11.38. The business has a fifty day simple moving average of $3.30 and a 200-day simple moving average of $5.27.

Neonc Technologies (NASDAQ:NTHI) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.03).

Analysts Set New Price Targets

Several research firms have recently issued reports on NTHI. Zacks Research upgraded shares of Neonc Technologies from a “strong sell” rating to a “hold” rating in a research note on Thursday, November 5th. BTIG Research reissued a “buy” rating and set a $15.00 price target on shares of Neonc Technologies in a research report on Tuesday, September 8th. Roth Capital started coverage on shares of Neonc Technologies in a research report on Thursday, September 24th. They set a “buy” rating on the stock. Weiss Ratings cut shares of Neonc Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, October 21st. Finally, Wall Street Zen raised shares of Neonc Technologies from a “sell” rating to a “hold” rating in a research report on Saturday, November 7th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.00.

Institutional Trading of Neonc Technologies

Hedge funds have recently bought and sold shares of the business. Bank of America Corp DE grew its stake in Neonc Technologies by 5.0% in the 1st quarter. Bank of America Corp DE now owns 235,396 shares of the company’s stock valued at $1,650,000 after purchasing an additional 11,108 shares during the period. Westmount Partners LLC raised its stake in shares of Neonc Technologies by 355.2% during the 2nd quarter. Westmount Partners LLC now owns 197,178 shares of the company’s stock worth $893,000 after purchasing an additional 153,858 shares during the period. BlackRock Inc. purchased a new position in shares of Neonc Technologies in the 2nd quarter worth about $815,000. Marshall Wace LLP boosted its holdings in shares of Neonc Technologies by 423.5% in the 3rd quarter. Marshall Wace LLP now owns 114,046 shares of the company’s stock worth $388,000 after buying an additional 92,262 shares during the last quarter. Finally, Global Retirement Partners LLC bought a new position in Neonc Technologies during the second quarter valued at about $126,000.

Neonc Technologies Company Profile

NeOnc Technologies Holdings, Inc. is a biotechnology company developing treatments for brain tumors and other central nervous system cancers. Its research focuses on approaches intended to deliver therapies to the brain, where the blood-brain barrier can limit the effectiveness of conventional treatments. The company’s pipeline includes NEO100, a formulation of perillyl alcohol designed for intranasal delivery, and NEO212, a compound combining perillyl alcohol with temozolomide. These candidates are being developed for potential use in brain cancer treatment.